Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Economic Impact of Advers… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Economic Impact of Adverse Drug Events – A Retrospective Population-Based Cohort Study of 4970 Adults

Artikel i vetenskaplig tidskrift
Författare Hanna Gyllensten
Katja M Hakkarainen
Staffan Hägg
Anders Carlsten
Max Petzold
Clas Rehnberg
Anna K Jönsson
Publicerad i PLoS ONE
Volym 9
Nummer/häfte 3
Sidor e92061
ISSN 1932-6203
Publiceringsår 2014
Publicerad vid Enheten för socialmedicin
Akademistatistik
Sidor e92061
Språk en
Länkar www.plosone.org/article/info%3Adoi%...
Ämnesord adverse drug event, medical records, cost-of-illness
Ämneskategorier Klinisk farmakologi, Samhällsfarmaci och klinisk farmaci, Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi, Epidemiologi, Folkhälsovetenskap

Sammanfattning

Background The aim was to estimate the direct costs caused by ADEs, including costs for dispensed drugs, primary care, other outpatient care, and inpatient care, and to relate the direct costs caused by ADEs to the societal COI (direct and indirect costs), for patients with ADEs and for the entire study population. Methods We conducted a population-based observational retrospective cohort study of ADEs identified from medical records. From a random sample of 5025 adults in a Swedish county council, 4970 were included in the analyses. During a three-month study period in 2008, direct and indirect costs were estimated from resource use identified in the medical records and from register data on costs for resource use. Results Among 596 patients with ADEs, the average direct costs per patient caused by ADEs were USD 444.9 [95% CI: 264.4 to 625.3], corresponding to USD 21 million per 100 000 adult inhabitants per year. Inpatient care accounted for 53.9% of all direct costs caused by ADEs. For patients with ADEs, the average societal cost of illness was USD 6235.0 [5442.8 to 7027.2], of which direct costs were USD 2830.1 [2260.7 to 3399.4] (45%), and indirect costs USD 3404.9 [2899.3 to 3910.4] (55%). The societal cost of illness was higher for patients with ADEs compared to other patients. ADEs caused 9.5% of all direct healthcare costs in the study population. Conclusions Healthcare costs for patients with ADEs are substantial across different settings; in primary care, other outpatient care and inpatient care. Hence the economic impact of ADEs will be underestimated in studies focusing on inpatient ADEs alone. Moreover, the high proportion of indirect costs in the societal COI for patients with ADEs suggests that the observed costs caused by ADEs would be even higher if including indirect costs. Additional studies are needed to identify interventions to prevent and manage ADEs.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?